Literature DB >> 16532349

Enhancement of anti-inflammatory tendency by SB203580, p38alpha specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A.

Seon Kyu Han1, Su Jin Jeon, Keiji Miyazawa, Seh Yoon Yi, Young Sook Yoo.   

Abstract

Interleukin-1 beta (IL-1beta) is an abundant cytokine, which, together with TNF-alpha, mediates inflammatory events in rheumatoid arthritis (RA). IL-1beta is known to induce the induction of inflammatory cytokines and metalloproteinases (MMPs) in rheumatoid synovial cells. Here, we assessed these inflammatory events by measuring IL-1beta levels in the human synovial cell line, MH7A. We observed that the activation of p38 MAP kinase by IL-1beta was involved in the induction of inflammatory cytokines, as well as several genes, including MMP-1 and MMP-3. SB203580, a specific p38 MAP kinase inhibitor, inhibited the production of IL-1beta-induced cytokines and MMPs, while the levels of the tissue inhibitor of metalloproteinase (TIMPs) were unchanged by treatment with SB203580. Moreover, the induction of suppressor of cytokine signaling 3 (SOCS3) and interferon regulatory factor 1 (IRF-1) were both found to be induced by the inhibition of p38 MAP kinase. Therefore, we suggested that the inhibition of p38 MAP kinase might enhance anti-inflammatory tendencies in the MH7A cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16532349     DOI: 10.1007/s00296-006-0109-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis.

Authors:  A Boe; M Baiocchi; M Carbonatto; R Papoian; O Serlupi-Crescenzi
Journal:  Cytokine       Date:  1999-12       Impact factor: 3.861

2.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.

Authors:  T Shouda; T Yoshida; T Hanada; T Wakioka; M Oishi; K Miyoshi; S Komiya; K Kosai; Y Hanakawa; K Hashimoto; K Nagata; A Yoshimura
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.

Authors:  A Bendele; T McAbee; G Sennello; J Frazier; E Chlipala; D McCabe
Journal:  Arthritis Rheum       Date:  1999-03

Review 4.  Role of cytokines in rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

5.  Cooperative interaction of nuclear factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines.

Authors:  N Mukaida; Y Mahe; K Matsushima
Journal:  J Biol Chem       Date:  1990-12-05       Impact factor: 5.157

Review 6.  Inhibition of IL-6 for the treatment of inflammatory diseases.

Authors:  Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

7.  Establishment and characterization of a novel human rheumatoid fibroblast-like synoviocyte line, MH7A, immortalized with SV40 T antigen.

Authors:  K Miyazawa; A Mori; H Okudaira
Journal:  J Biochem       Date:  1998-12-01       Impact factor: 3.387

8.  Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

Authors:  D Wendling; E Racadot; J Wijdenes
Journal:  J Rheumatol       Date:  1993-02       Impact factor: 4.666

9.  Interleukin 6 plays a key role in the development of antigen-induced arthritis.

Authors:  S Ohshima; Y Saeki; T Mima; M Sasai; K Nishioka; S Nomura; M Kopf; Y Katada; T Tanaka; M Suemura; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Interleukin 6 is required for the development of collagen-induced arthritis.

Authors:  T Alonzi; E Fattori; D Lazzaro; P Costa; L Probert; G Kollias; F De Benedetti; V Poli; G Ciliberto
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

View more
  6 in total

1.  Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-alpha signaling.

Authors:  Cindy Zer; George Sachs; Jai Moo Shin
Journal:  Physiol Genomics       Date:  2007-07-24       Impact factor: 3.107

2.  sb203580 preconditioning recharges matrix-expanded human adult stem cells for chondrogenesis in an inflammatory environment - A feasible approach for autologous stem cell based osteoarthritic cartilage repair.

Authors:  Ying Zhang; Tyler Pizzute; Jingting Li; Fan He; Ming Pei
Journal:  Biomaterials       Date:  2015-06-20       Impact factor: 12.479

3.  Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.

Authors:  Devki Sukhtankar; Alec Okun; Anupama Chandramouli; Mark A Nelson; Todd W Vanderah; Anne E Cress; Frank Porreca; Tamara King
Journal:  Mol Pain       Date:  2011-10-20       Impact factor: 3.395

Review 4.  Role of suppressors of cytokine signaling 3 in bone inflammatory responses.

Authors:  Anqi Gao; Thomas E Van Dyke
Journal:  Front Immunol       Date:  2014-01-10       Impact factor: 7.561

5.  Glucosamine Downregulates the IL-1β-Induced Expression of Proinflammatory Cytokine Genes in Human Synovial MH7A Cells by O-GlcNAc Modification-Dependent and -Independent Mechanisms.

Authors:  Akimasa Someya; Takako Ikegami; Koji Sakamoto; Isao Nagaoka
Journal:  PLoS One       Date:  2016-10-24       Impact factor: 3.240

6.  Adenosine inhibits TNFα-induced MMP-3 production in MH7A rheumatoid arthritis synoviocytes via A2A receptor signaling.

Authors:  Hiroe Konishi; Shun-En Kanou; Rika Yukimatsu; Mizuki Inui; Motoya Sato; Naruto Yamamoto; Masayoshi Nakano; Masahiro Koshiba
Journal:  Sci Rep       Date:  2022-04-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.